On pharmaceutical products:
We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.
ELI LILLY & Co (LLY) single-company analysis
This page is a descriptive assembly from a frozen evidence pack of public SEC filing excerpts and verified SEC companyfacts metrics. It is not a rating, recommendation, endorsement, forecast, valuation, or investment advice. Filer viewpoints are attributed to the filer and figures are as of their cited filing dates.
Informational only - not investment advice. See Disclaimer.
Back to LLY company profile. Existing company-page SVG figures remain the source for financial time-series context.
Business & segments
On local marketing methods:
We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
Financial profile
The values below are templated from verified SEC companyfacts-derived facts. The embedded SVG figures show selected annual series from the same facts.
Reported revenue: 65,179,000,000
Net margin: 31.67%
Share buybacks: 4,108,000,000
Revenue scale is shown from verified SEC companyfacts. Revenue: 65,179,000,000
Net margin is shown from verified SEC companyfacts. Net margin: 31.67%
Dividends paid are shown as reported cash outflow magnitude from verified SEC companyfacts. Dividends paid: 5,384,000,000
Share buybacks are shown as reported cash outflow magnitude from verified SEC companyfacts. Share buybacks: 4,108,000,000
| Metric | Value | Fiscal year | Period end | Source |
|---|---|---|---|---|
| Dividends paid | 5,384,000,000 | 2025 | 2025-12-31 | USD |
| Net income | 20,640,000,000 | 2025 | 2025-12-31 | USD |
| Net margin | 31.67% | 2025 | 2025-12-31 | Percent |
| Operating cash flow | 16,813,000,000 | 2025 | 2025-12-31 | USD |
| Revenue | 65,179,000,000 | 2025 | 2025-12-31 | USD |
| Return on assets | 18.35% | 2025 | 2025-12-31 | Percent |
| Return on equity | 77.78% | 2025 | 2025-12-31 | Percent |
| Share buybacks | 4,108,000,000 | 2025 | 2025-12-31 | USD |
Stated strategy
Key idiosyncratic risks
On biologics regulation:
Given the importance to us of marketed biologic products and those in our clinical-stage pipeline, such regulation could have a material adverse effect on our business.
On competition:
We face intense competition for qualified individuals from numerous multinational companies, academic and other research institutions, as well as employers near our manufacturing and other facilities, which has increased and may continue to increase our labor costs.
On intense product competition:
We and our products face intense competition, and such competition could have a material adverse effect on our business.
Recent developments
On Zepbound revenue:
Revenue of Zepbound increased 174 percent in the U.S., driven by increased demand, partially offset by lower realized prices.
On research-and-development expense movement:
Research and development expenses increased 21 percent in 2025, primarily driven by continued investments in our early and late-stage portfolio.
On net-income and earnings movement:
Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.